TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Marinus ( (MRNS) ) is now available.
On February 11, 2025, Immedica Pharma AB completed its acquisition of Marinus Pharmaceuticals, Inc., following a successful tender offer to purchase all outstanding shares for $0.55 per share. This transaction resulted in Marinus becoming an indirect wholly-owned subsidiary of Immedica, leading to the delisting of Marinus’ common stock from NASDAQ. The acquisition led to significant changes in Marinus’ management, with new appointments and the termination of former directors and officers. The total consideration for the merger was approximately $32.3 million, excluding related transaction fees and expenses.
More about Marinus
Marinus Pharmaceuticals is a commercial-stage pharmaceutical company focused on developing innovative therapeutics for seizure disorders. Its primary product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved medication for seizure management, introduced in the United States in 2022.
YTD Price Performance: 3.00%
Average Trading Volume: 1,813,180
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $30.34M
For a thorough assessment of MRNS stock, go to TipRanks’ Stock Analysis page.